News: stock, crypto, macro, education

IQVIA Reports Strong Second-Quarter 2024 

IQVIA Reports Strong Second-Quarter 2024 

IQVIA Holdings Inc. (NYSE: IQV), a leader in advanced analytics, technology solutions, and clinical research services for the life sciences industry, has announced its financial results for the second quarter of 2024. Despite strong performance metrics, the company's stock saw a premarket decline of 0.5%.

Key Highlights from the Second Quarter 2024:

  1. Revenue Growth:

    • Total revenue reached $3.814 billion, a 2.3% increase compared to the second quarter of 2023.
    • On a constant currency basis, revenue grew by 3.5%.
  2. Segment Performance:

    • Technology & Analytics Solutions (TAS): Revenue was $1.495 billion, increasing by 2.7% reported and 3.8% at constant currency.
    • Research & Development Solutions (R&DS): Revenue was $2.147 billion, growing by 2.4% reported and 3.3% at constant currency. Excluding pass-throughs, R&DS revenue increased by 3.5%.
    • Contract Sales & Medical Solutions (CSMS): Revenue was $172 million, a decrease of 2.3% reported but an increase of 2.8% at constant currency.
  3. Profitability:

    • GAAP Net Income was $363 million.
    • Adjusted EBITDA was $887 million, a year-over-year increase of 2.7%.
    • GAAP Diluted Earnings per Share (EPS) were $1.97, while Adjusted Diluted EPS were $2.64.
  4. Bookings and Backlog:

    • R&D Solutions quarterly bookings reached $2.7 billion, with a book-to-bill ratio of 1.27x.
    • Contracted backlog for R&D Solutions was $30.6 billion, a 7.7% year-over-year increase reported, and 8.1% at constant currency. Approximately $7.8 billion of this backlog is expected to convert to revenue in the next twelve months.

Updated Full-Year 2024 Guidance:

  • Revenue: $15,425 million to $15,525 million.
  • Adjusted EBITDA: $3,705 million to $3,765 million.
  • Adjusted Diluted EPS: $11.10 to $11.30.

CEO Commentary:

Ari Bousbib, Chairman and CEO of IQVIA, highlighted the company's strong operational execution and better-than-expected TAS performance as key drivers for the quarter's results. He emphasized that profit margins expanded, free cash flow was strong, and adjusted diluted EPS grew by 8.6%. The R&DS segment continued to perform well, reflecting high demand for IQVIA's solutions. Forward-looking indicators, such as RFP flow and a healthy qualified pipeline, suggest a positive outlook for the company.

Market Reaction:

Despite the positive financial performance, IQVIA's stock price dipped by 0.5% in premarket trading. This reaction may be attributed to broader market conditions or investor expectations not fully aligning with the reported results.

Source: Iqvia

More articles